Cargando…
An advanced pulmonary sarcomatoid carcinoma patient harboring a BRAF(V600E) mutation responds to dabrafenib and trametinib: a case report and literature review
BACKGROUND: The pulmonary sarcomatoid carcinoma (PSC) is a rare and aggressive subtype of NSCLC with rapid progression and poor prognosis, and is resistant to conventional chemotherapy. Most PSC cases have potential targetable genomic alterations. Approximately 7% of PSC patients have BRAF mutations...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10403232/ https://www.ncbi.nlm.nih.gov/pubmed/37546400 http://dx.doi.org/10.3389/fonc.2023.1220745 |